Dopamine depletion does not protect against acute 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine toxicity in vivo

Daphne M. Hasbani, Francisco A. Perez, Richard D. Palmiter, Karen L. O'Malley

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Dopamine (DA) has been postulated to play a role in the loss of dopaminergic substantia nigra (SN) neurons in Parkinson's disease because of its propensity to oxidize and form quinones and other reactive oxygen species that can alter cellular function. Moreover, DA depletion can attenuate dopaminergic cell loss in vitro. To test the contribution of DA to SN impairment in vivo, we used DA-deficient mice, which lack the enzyme tyrosine hydroxylase in dopaminergic cells, and mice pharmacologically depleted of DA by α-methyl-p-tyrosine pretreatment. Mice were treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a toxin that produces parkinsonian pathology in humans, nonhuman primates, and rodents. In contrast to in vitro results, genetic or pharmacologic DA depletion did not attenuate loss of dopaminergic neurons in the SN or dopaminergic neuron terminals in the striatum. These results suggest that DA does not contribute to acute MPTP toxicity in vivo.

Original languageEnglish
Pages (from-to)9428-9433
Number of pages6
JournalJournal of Neuroscience
Volume25
Issue number41
DOIs
StatePublished - Oct 12 2005

Keywords

  • Animal models
  • Dopamine
  • MPTP
  • Neurodegeneration
  • Parkinson's disease
  • Substantia nigra

Fingerprint Dive into the research topics of 'Dopamine depletion does not protect against acute 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine toxicity in vivo'. Together they form a unique fingerprint.

  • Cite this